<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589186</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000579355</org_study_id>
    <secondary_id>SINGAPORE-NCC-07-11-NPC</secondary_id>
    <nct_id>NCT00589186</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer</brief_title>
  <official_title>Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help&#xD;
      the body build an effective immune response to kill tumor cells. Celecoxib may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine&#xD;
      therapy together with celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving vaccine therapy together with&#xD;
      celecoxib works in treating patients with metastatic nasopharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the clinical benefit rate (complete response, partial response, and stable&#xD;
           disease for ≥ 14 weeks) in patients with metastatic nasopharyngeal carcinoma treated&#xD;
           with autologous dendritic cells (DC) transduced with AD5F35 expressing LMP-1 and LMP-2&#xD;
           when administered in combination with celecoxib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the toxicities of this regimen in these patients.&#xD;
&#xD;
        -  To evaluate the specific T-cell response against LMP-1 and LMP-2 as measured by HLA&#xD;
           tetramer technology, ELISPOT assay, and delayed-type hypersensitivity in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  To evaluate the surrogate tumor marker response plasma EBV DNA by real-time PCR in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate and characterize immunological cell types and tumor characteristics in&#xD;
           biopsy specimens of patients treated with this DC vaccine and compare it with&#xD;
           pre-vaccine biopsy specimens.&#xD;
&#xD;
        -  To evaluate progression-free survival and overall survival of patients who show initial&#xD;
           clinical benefit to DC vaccine.&#xD;
&#xD;
      OUTLINE: Patients undergo blood collection for the preparation of the autologous dendritic&#xD;
      cell (DC) vaccine. Immature DCs are transduced with latent membrane protein-1 (LMP-1) and&#xD;
      latent membrane protein-2 (LMP-2) using the adenoviral vector 5F35. Beginning 1 week after&#xD;
      blood collection, patients receive vaccination with autologous DCs transduced with&#xD;
      AD5F35-LMP-1/LMP-2 intradermally every 2 weeks for a total of 5 vaccinations. Patients also&#xD;
      receive celecoxib twice a day beginning 1 week before the first vaccination and continuing&#xD;
      for up to 6 weeks after completion of the last vaccination.&#xD;
&#xD;
      Patients who demonstrate clinical benefit after completion of 5 courses of vaccination may&#xD;
      continue to receive the DC vaccine alone off study every 2 weeks until disease progression&#xD;
      (based on CT scan findings) or at the investigator's discretion.&#xD;
&#xD;
      Patients undergo blood and tumor tissue sample collection periodically for laboratory&#xD;
      studies. Blood samples are analyzed using MHC tetramer analysis; enzyme-linked immunospot&#xD;
      (ELISPOT) analysis; EBV DNA titers to assess response; and flow cytometry to assess&#xD;
      lymphocyte kinetics. Tumor tissue samples are used for immunological studies. Delayed-type&#xD;
      hypersensitivity is also assessed.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate (CBR) (complete response [CR], partial response [PR], and stable disease [SD] for ≥ 14 weeks) as defined by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR and PR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5F35-LMP1/LMP2-transduced autologous dendritic cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed nasopharyngeal carcinoma (NPC)&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  WHO type II/III disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Progression on one or more lines of polychemotherapy for treatment of metastatic&#xD;
                  disease&#xD;
&#xD;
               -  Failed non-myeloablative hematopoietic stem cell transplant&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  ALT or AST ≤ 5 times normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 45% by MUGA&#xD;
&#xD;
          -  Corrected DLCO &gt; 50% of predicted&#xD;
&#xD;
          -  No active or prior gastrointestinal bleeding&#xD;
&#xD;
          -  No history of adverse reaction to NSAIDs or sensitivity to celecoxib&#xD;
&#xD;
          -  No cardiac disease, including any of the following:&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Active angina pectoris&#xD;
&#xD;
               -  High-risk uncontrolled arrhythmia&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
          -  No pulmonary disease, including any of the following:&#xD;
&#xD;
               -  Severe chronic obstructive lung disease&#xD;
&#xD;
               -  Uncontrolled large pleural effusion&#xD;
&#xD;
               -  Severe restrictive lung disease&#xD;
&#xD;
          -  No cerebrovascular accident&#xD;
&#xD;
          -  No transient ischemic attack&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No symptomatic leukoencephalopathy or other neuropsychiatric abnormalities&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior celecoxib allowed&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  At least 100 days since prior non-myeloablative hematopoietic stem cell transplant&#xD;
&#xD;
          -  At least 2 months since prior donor lymphocyte infusions&#xD;
&#xD;
          -  More than 28 days since prior participation in another clinical trial with any&#xD;
             investigational drugs&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent anticoagulation with warfarin or low molecular weight heparin&#xD;
&#xD;
          -  No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toh Han Chong, MD, MBBS, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

